Skip to main content
. 2020 Jun 15;2(5):100137. doi: 10.1016/j.jhepr.2020.100137

Table 1.

Baseline characteristics of study participants.

Characteristics NAFLD cirrhosis (n = 15) Non-cirrhotic NAFLD (n = 14) Healthy controls (n = 14) p value
Women (%) 4 (27) 5 (36) 9 (64) 0.70
Age (years) 69 (44–76) 60 (29–75) 39 (20–59) <0.001
Height (m) 1.73 (1.56–1.81) 1.72 (1.50–1.87) 1.72 (1.54–1.84) 0.93
Weight (kg) 96.4 (76–118) 103.8 (73.4–126.8) 61.45 (48.7–74.7) <0.001
BMI (kg/m2) 34.2 (25.4–37.8) 35 (30.9–39.8) 21.6 (18.6–24.7) <0.001
Waist circumference (cm) <0.001
 Women 110 (100–119) 106 (95–126) 74 (64.5–80)
 Men 110 (96–130) 110 (106–136) 80 (73–85)
Smoking status (%) 0.16
 Current smoker 1 (7) 2 (14) 1 (7)
 Ex-smoker 5 (33) 2 (14) 0 (0)
 Non-smoker 9 (60) 10 (72) 13 (93)
Alcohol (units/week) 0 (0–10) 1 (0–7) 2.5 (0–10) 0.20
Coffee consumption(cups/day) 3 (0–7) 2 (0–7) 2 (0–4) 0.15
Modality of diagnosis 0.16
 Histology 2 (13) 5 (35)
 Non-invasive 13 (87) 9 (65)
 Elastography
 TE 17 (8.6) 8.9 (5.1) <0.001
 ARFI 3.2 (1.3)
 Hyaluronic acid (μg/L) 200 (241)± 40 (30) <0.001
 Fibrosis score
 APRI score 0.42 (0.33) 0.24 (0.15) 0.007
 NAFLD fibrosis score 1.54 (1.17) –0.38 (1.66) 0.017
 Fib-4 score 2.31 (1.15) 1.39 (0.77) 0.004
 BARD Score 4 (1) 3 (3) 0.082
Laboratory parameters
 HbA1c (IFCC) 54 (36–103) 49 (32–94) 1.00
 HOMA 4.45 (2.7–6.2)ˆ 5.35 (1.7–6.9)ˆˆ 0.91
 GGT (U/L) 147 (44–843) 61 (22–387) 0.07
 Albumin (g/L) 36 (31–40) 39 (35–44) 0.02
 AST (U/L) 32 (25–71) 27 (21–78) 0.27
 ALT (U/L) 55 (14–69) 44 (16–115) 0.14
 Platelets (109/L) 210 (61–271) 229 (108–289) 0.14

Data presented as median and IQR or frequency (n) and percentage where appropriate. Student’s t test or Mann-Whitney U test were used to compare normally distributed continuous variables and non-parametrically distributed data, respectively.

ALT, alanine aminotransaminase; ARFI, acoustic radiation force impulse; AST, aspartate aminotransferase; BMI, body mass index; GGT, gamma-glutamyltransferase; HOMA, homeostatic model assessment; NAFLD, non-alcoholic fatty liver disease; TE, transient elastography.

n = 10.

n = 3.

±

n = 13.

ˆ

n = 2.

ˆˆ

n = 6.